The announcement comes after Austria stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.

此前，奧地利在調查一起凝血障礙死亡事件和一起肺栓塞疾病時，停止使用一批阿斯利康針劑。

Still, the use medicine regulator said the vaccine's benefits outweighed the risks and could continue to be administered.

不過，用藥監管部門還是表示，疫苗的好處大於風險，可以繼續接種。

Denmark suspended the AstraZeneca shots for two weeks after a 60 year old woman who was given a shot from the same batch used in Austria, formed a blood clot and died, Denmark said.

丹麥表示，丹麥暫停阿斯利康注射兩週，因為一名60歲的婦女在奧地利使用的同一批次的注射中，形成血栓並死亡。

The suspension was also prompted by reports quote of possible serious side effects from other European countries.

暫停也促使報道引用其他歐洲國家可能的嚴重副作用。

Some health experts said there was little evidence to suggest the AstraZeneca vaccine should not be administered.

一些衛生專家說，沒有什麼證據表明不應該接種阿斯利康疫苗。

One expert told Reuters.

一位專家告訴路透社。

It's extremely difficult to distinguish a causal effect from a coincidence.

要區分一個因果和一個巧合是非常困難的。

AstraZeneca told Reuters in a written statement that the safety of its vaccine had been extensively studied in human trials, and peer reviewed data confirmed it was generally well tolerated.

阿斯利康在一份書面聲明中告訴路透社，其疫苗的安全性已經在人體試驗中進行了廣泛的研究，同行評議的數據證實它的耐受性普遍良好。

The drug maker said this week there had been quote no confirmed serious adverse events associated with the vaccine.

該藥物製造商本週表示，已經報價沒有證實與疫苗相關的嚴重不良事件。

It also said it was in contact with Austrian authorities about the death and would fully support their investigation.

它還說，它正就這起死亡事件與奧地利當局聯繫，並將全力支持他們的調查。